Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study

Trobec, Katja; Grabnar, Iztok; Kos, Mojca Kerec; Vovk, Tomaž; Trontelj, Jurij; Anker, Stefan D.; Rosano, Giuseppe; Lainščak, Mitja

doi:10.1007/s00228-016-2041-1

Cited by 17 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous Pop-PK studies in healthy individuals, and patients with chronic heart failure, have reported mean bisoprolol clearances of 15.6 L/h 3 and 10.2 L/h. 11 The clearance observed in our study is in alignment with previous findings despite the differences in patient populations studied, study design, sampling times and modelling algorithms, all of which may influence the results. In our model, older age and lower body weight were most strongly associated with reduced bisoprolol clearance.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Fontana

Turner

Francis

et al. 2022

PGPM

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

“…The model and the initial values were obtained from a previous bisoprolol PK study in patients with chronic heart failure. 11 …”

Section: Methodsmentioning

confidence: 99%

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Fontana

Turner

Francis

et al. 2022

PGPM

View full text Add to dashboard Cite

“…30 Treatment with β-blockers can increase total body fat mass and total body fat content in patients with HF, without apparent improvement in muscle mass. 30,31 In this study, we did not observe differences between groups in β-blocker treatment and dosage. In this context, future randomized clinical trials are required to assess the real impact of β-blocker therapy on skeletal muscle mass in patients with HF.…”

Section: Discussioncontrasting

confidence: 51%

Sympatho-Vagal Imbalance is Associated with Sarcopenia in Male Patients with Heart Failure

Fonseca¹,

Santos²,

Souza³

et al. 2019

Arquivos Brasileiros De Cardiologia

Self Cite

View full text Add to dashboard Cite

Background Resting sympathetic hyperactivity and impaired parasympathetic reactivation after exercise have been described in patients with heart failure (HF). However, the association of these autonomic changes in patients with HF and sarcopenia is unknown. Objective The aim of this study was to evaluate the impact of autonomic modulation on sarcopenia in male patients with HF. Methods We enrolled 116 male patients with HF and left ventricular ejection fraction < 40%. All patients underwent a maximal cardiopulmonary exercise testing. Maximal heart rate was recorded and delta heart rate recovery (∆HRR) was assessed at 1 st and 2 nd minutes after exercise. Muscle sympathetic nerve activity (MSNA) was recorded by microneurography. Dual-energy X-ray absorptiometry was used to measure body composition and sarcopenia was defined by the sum of appendicular lean muscle mass (ALM) divided by height in meters squared and handgrip strength. Results Sarcopenia was identified in 33 patients (28%). Patients with sarcopenia had higher MSNA than those without (47 [41-52] vs. 40 [34-48] bursts/min, p = 0.028). Sarcopenic patients showed lower ∆HRR at 1 st (15 [10-21] vs. 22 [16-30] beats/min, p < 0.001) and 2 nd min (25 [19-39] vs. 35 [24-48] beats/min, p = 0.017) than non-sarcopenic. There was a positive correlation between ALM and ∆HRR at 1 st (r = 0.26, p = 0.008) and 2 nd min (r = 0.25, p = 0.012). We observed a negative correlation between ALM and MSNA (r = -0.29, p = 0.003). Conclusion Sympatho-vagal imbalance seems to be associated with sarcopenia in male patients with HF. These results highlight the importance of a therapeutic approach in patients with muscle wasting and increased peripheral sympathetic outflow.

show abstract

“…Three of these were popPK studies, 28,29,34 1 was a cross-sectional study, 30 and 3 were prospective observational studies. [31][32][33] Carvedilol. The sample size of carvedilol studies ranged from 41 to 58 patients with HF and the doses ranged from 1.25 to 50 mg daily.…”

Section: β-Blockersmentioning

confidence: 99%

Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Objective: To conduct a review of studies evaluating the influence of body size and weight (WT) on the pharmacokinetics (PK) of drugs recommended for heart failure (HF) treatment. Data Sources: A systematic search of the MEDLINE (1946 to April 2023) and EMBASE (1974 to April 2023) databases was conducted for articles that focused on the impact of WT or body size on the PK of drugs of interest used in HF patients. Study Selection and Data Extraction: Articles written in English or French related to the aim of our study were retained for analysis. Data Synthesis: Of 6493 articles, 20 were retained for analysis. Weight was associated with the clearance of digoxin, carvedilol, enalapril, and candesartan as well as the volume of distribution of eplerenone and bisoprolol. There was no documented direct impact of WT on the PK of furosemide, valsartan, and metoprolol, although these studies were limited or confounded by the small sample size, adjustment of PK factors by WT, or the use of the Cockroff-Gault equation for the evaluation of creatinine clearance, which includes WT. Relevance to Patient Care and Clinical Practice: This review highlights and summarizes the available data on the importance of WT on the PK of HF treatment. Conclusion: Considering the significant impact of WT on most HF drugs in this review, it may be important to further investigate it in the context of personalized therapy, particularly in patients presenting extreme WTs.

show abstract

Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study

Cited by 17 publications

References 37 publications

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Sympatho-Vagal Imbalance is Associated with Sarcopenia in Male Patients with Heart Failure

Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review

Contact Info

Product

Resources

About